BrainsWay's Platform Pivot: From Deep TMS to Interventional Psychiatry

Q2 2026 accelerates 35% revenue growth, raises guidance, and expands minority investments as SWIFT and PTSD broaden the addressable market.

BWAY.TA · Earnings Call · 2026-08-12

The Quarter in Numbers

BrainsWay reported a 35% revenue increase to $17.1 million for Q2 2026, with operating income surging more than 300% to $2.4 million and adjusted EBITDA up 141% to $3.5 million — the 12th consecutive quarter of profitability. The company raised full-year 2026 guidance to $68–70 million, representing 30–34% year-over-year growth.

we are raising our full year 2026 guidance from a range of $66 million to $68 million to a range of $68 million to $70 million
Ido Marom, Unknown - likely an executive or senior management · 2026-08-12

From Deep TMS to Interventional Psychiatry

Management framed the quarter as a strategic inflection point. “we believe BrainsWay is entering the next phase of its evolution from a leading Deep TMS company into a broader platform for interventional psychiatry” — Hadar Levy, Chief Executive Officer · 2026-08-12 This pivot is anchored by expanding interventional psychiatry reimbursement and a minority investment strategy that seeds a growing ecosystem of behavioral health providers. Six minority investments now include HopeMark Health, Radial Health, and Sound Minds Behavioral. Each partnership is designed to drive system utilization and orders. As Hadar explained, “each one of them can expand to 10 to 15 locations every year” — Hadar Levy, Chief Executive Officer · 2026-08-12 — creating a compounding demand loop for the Deep TMS platform.

SWIFT: The Reimbursement Engine

The SWIFT protocol is accelerating adoption. With ~57 million covered lives and growing, the feedback from providers is overwhelmingly positive. “The feedback is very, very strong and very good” — Hadar Levy, Chief Executive Officer · 2026-08-12 Where reimbursement exists, SWIFT can capture close to 50% of the local MDD population. This shift is not just convenience; durability data presented this quarter showing sustained remission at 12 months strengthens the payer case.

Continuity from Prior Calls

The current strategy builds on themes management has been telegraphing for quarters. A year ago, Hadar set a target of signing at least five minority contracts by year-end: “The goal – my personal goal and the company goal is to sign at least 5 contracts before the end of the year” — Hadar Levy, Chief Executive Officer · 2025-08-13 He also anticipated SWIFT reimbursement expansion: “we do expect to get reimbursement by payers for, I would say, 40 million to 50 million covered lives before the end of the year” — Jeffrey Cohen, Analyst · 2025-11-11 (from the May 2026 call). That forecast is now being realized — and even exceeded.

PTSD: Another Indication Catalyst

The company presented real-world data on 462 patients with comorbid PTSD and MDD, showing >83% response in PTSD symptoms. The FDA submission is already in, and clearance would expand utility across the installed base without new capital. This aligns with a long-running goal: “we do expect to receive the FDA clearance before the end of the year” — Hadar Levy, Chief Executive Officer · 2026-05-13 (from the May 2026 call).

Why This Matters

BrainsWay is not just executing on a growth plan; it is redefining its identity. The shift to an interventional psychiatry platform – evidenced by interventional psychiatry becoming the top keyword in its own earnings narrative and six minority investments – positions the company at the forefront of a nascent but expanding field. With a debt-free balance sheet, $62.4 million in cash, and an $80.4 million RPO backlog, the financial foundation supports continued investment and upside. The market has yet to fully price in the breadth of this platform evolution, making this a name worth watching closely.